Hikma agrees MENA deal to distribute Perrigo's OTC products

Hikma Pharmaceuticals has signed a licensing and distribution agreement to distribute more than 30 of Perrigo's over-the-counter consumer healthcare products in the Middle East and North Africa.

Hikma has been given an exclusive right to license and distribute products including Davitamon, Prevalin, XLS Medical, Dermalex and Paranix in all of the Perrigo's MENA markets, with the exception of current agreements in place.

In addition, Hikma has the right of first refusal to the full range of the US-listed, Dublin-headquartered company’s over-the-counter medicines in the region.

Hikma said the agreement will leverage is "substantial local presence with operations in 17 markets and an established sales and marketing team, experienced in building brands, with particular expertise in the consumer health business".

Executive vice chairman Mazen Darwazah, who heads up Hikma's MENA and emerging markets team, said, “This agreement will expand our consumer healthcare portfolio, enabling us to meet growing demand across the region.”

Perrigo's consumer healthcare boss Svend Andersen stated, “These OTC medicines are important in meeting the healthcare needs of patients and consumers. We are pleased to partner with Hikma to leverage their strong presence in MENA markets, further increasing access to these valuable consumer products."